New grant: Ox4TB Philip Fowler, 17th March 202517th March 2025 Very pleased to announce that I am a co-investigator on the recently announced Oxford4TB project that has been funded by the Ineos Oxford Institute for antimicrobial research (IOI). The project will received £5 million over three years and the main aim is to develop new therapies for multi-drug resistant tuberculosis. We will be guiding the selection of targets and leads using our large dataset of >50k clinical tuberculosis samples. Each sample has phenotypic drug susceptibility testing and whole genome data so we will be able to e.g. check there are no mutations in circulation that could lead to resistance of any new compound. I will be advertising a post to work on this project in a few months time. Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Related antimicrobial resistance clinical microbiology tuberculosis
antimicrobial resistance New publication: Predicting resistance is (not) futile 21st August 201921st August 2019 Our “First Reactions” article has been published in ACS Central Science. We discuss the paper,… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance New paper: What can subpopulations tell us about rifampicin resistance? 14th October 202514th October 2025 Last Thursday this work which we’d previously preprinted looking at looking at rifampicin-resistant subpopulations in… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More
New publication: CRyPTIC GWAS of antitubercular resistance 16th August 202216th August 2022 Since the primary goal of CRyPTIC was to map the genetic variants in M. tuberculosis… Share this: Click to share on X (Opens in new window) X Click to share on Bluesky (Opens in new window) Bluesky Click to email a link to a friend (Opens in new window) Email Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Mastodon (Opens in new window) Mastodon Read More